Evidence map›Paper›PMID 37249280›Full record

Trial reportImmunity, inflammation and disease2023

Efficacy of diet restriction with or without probiotic for treatment of patients with IBS-D: Phase I-II clinical trial.

Xian-Shu Zhao, Li-Jun Shi, Bao-Li Ning, Zhi-Ming Zhao, Xiao-Xue Li, Meng-Hua Zhu, Ya-Bing Zhang, Jun Fu

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xian-Shu ZhaoHealth Center of Screening and Prevention of Diseases, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Li-Jun ShiDepartment of gastroenterology, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Bao-Li NingHealth Center of Screening and Prevention of Diseases, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Zhi-Ming ZhaoHealth Center of Screening and Prevention of Diseases, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Xiao-Xue LiDepartment of gastroenterology, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Meng-Hua ZhuDepartment of gastroenterology, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Ya-Bing ZhangDepartment of gastroenterology, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Jun FuHealth Center of Screening and Prevention of Diseases, First Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID 0000-0002-7946-4208

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimDiet is a major contributor to irritable bowel syndrome (IBS) and is also a powerful tool for treatment of IBS. This study compared two diets and explored the effectiveness of the diets when combined with a probiotic for treatment of IBS-D patients.

methodsPhase I, patients were randomized into groups; control, cold/spicy/fried restricted diet (CSF res diet), IgG positive restricted diet (IgG res diet), and a combination both diets (CSF + IgG res diet). Phase II, patients were randomized into IgG res diet + placebo and IgG res diet + probiotic. Both interventions were 12 weeks in duration. Symptom Severity Scale (IBS-D-SSS) and IgG titer were assessed at the beginning and the end of the study.

resultsTotals of 214 and 167 patients completed the two parts of the study, respectively. After intervention, IBS-D-SSS and TIgG grade were significantly improved compared to baseline, with results similar to the control group. In general, there were decreases in IBS-D-SSS and TIgG grade that were significantly different among the groups. There were exceptions; no differences were observed for IBS-D-SSS between the IgG res diet and CSF + IgG res diet, or TIgG grade between the CSF res diet, IgG res diet, and CSF + IgG res diet. However, the CSF res diet and IgG res diet had a synergistic effect that decreased IBS-D-SSS and TIgG titer, with a greater contribution by the IgG res diet. Therefore, we evaluated the IgG res diet with either placebo or probiotic and found that IBS-D-SSS and TIgG grade decreased from baseline. There was a significant decrease in IBS-D-SSS with the probiotic but TIgG grade was not significantly different between the IgG diet + placebo and IgG diet + probiotic diet.

conclusionsBoth the CSF res diet and IgG res diet improved IBS symptoms and demonstrated synergy, although the IgG res diet had a greater contribution. Further, when intolerant foods cannot be eliminated from a diet, avoiding uncooked, cold, spicy, fried, and alcoholic foods is a superior choice. The IgG res diet combined with Bifidobacteria was the best dietary choice and may function though a non-IgG pathway.

Indexed as

Irritable Bowel SyndromeProbioticsDietHumansQuality of LifeSeverity of Illness IndexBifidobacteriadiarrhea-predominant irritable bowel syndromeIBS-SSSIgG antibody titersprobioticrestricted diet

Identifiers

PMID37249280
PMCPMC10165954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.